Folinic acid
Based on 17 publication(s) in Google Scholar
Folinic acid (Leucovorin) is a biological folic acid and is generally administered along with Methotrexate (HY-14519) as a rescue agent to decrease MTX-induced toxicity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.98%
- CAS No.: 58-05-9
- Formule: C20H23N7O7
- Masse moléculaire:473.44
-
Stockage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Folinic acid
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
- JAMA Oncol. 2022 Jan 1;8(1):e215445. [Abstract]
- Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
- EBioMedicine. 2024 Apr:102:105041. [Abstract]
- NPJ Precis Oncol. 2023 Dec 8;7(1):128. [Abstract]
- Mol Cancer Ther. 2025 Dec 4. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Appl Microbiol Biotechnol. 2024 Dec;108(1):1-15. [Abstract]
- Mol Oncol. 2026 Jun 5. [Abstract]
- Mol Oncol. 2020 Nov;14(11):2894-2919. [Abstract]
- Int J Immunopathol Pharmacol. 2025 Jan-Dec:39:3946320251338662. [Abstract]
- Virology. 2023 Aug:585:205-214. [Abstract]
- Oncol Lett. 2026 Mar 4;31(5):155. [Abstract]
- bioRxiv. 2025 Sep 17.
- Patent. US20230101335A1.
- bioRxiv. 2023 Feb 28.
Customer Validation & Images
-
Flow Cytometry
-
Flow Cytometry
-
WB
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
Human Endogenous Metabolite |
Methotrexate (MTX) alone induces a concentration-related increase in % micronucleated binucleated cells (MNBN) and % aberrant cells (Abs). There is a decrease in nuclear division index (NDI) with increase in MTX concentration. Similarly, the mitotic index (MI) also decreases in all concentrations of MTX tested. The addition of Folinic acid at 50 μg/ mL significantly reduces % MNBN (40-68%) and % Abs (36-77%). Inhibition is also seen at 5 μg/ mL Folinic acid (12 to 54% for MNBN and 20 to 61% for Abs) [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:24 Balb/c young growing male mice aged 3 weeks (11.88 ± 0.25 g)[2]
-
Dosage:7.0 mg/kg
-
Administration:Intraperitoneal injection; every second day; for 3 weeks
-
Result:Following MTX administration appears to reverse this growth inhibition.
Chemical Information
-
CAS No. 58-05-9
-
Appearance Solid
-
Masse moléculaire 473.44
-
Formule C20H23N7O7
-
Color Off-white to light yellow
-
SMILES
O=C(O)CC[C@@H](C(O)=O)NC(C1=CC=C(NCC2N(C=O)C3=C(N=C(N)NC3=O)NC2)C=C1)=O
-
Synonyms
leucovorin
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Cancer Cell
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]2026 Mar 9;44(3):658-675.e12. PMID: 41687606 -
JAMA Oncol
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. [Abstract]2022 Jan 1;8(1):e215445. PMID: 34792531 -
Nat Commun
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]2020 Apr 14;11(1):1792. PMID: 32286289 -
EBioMedicine
Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3. [Abstract]2024 Apr:102:105041. PMID: 38484555 -
NPJ Precis Oncol
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. [Abstract]2023 Dec 8;7(1):128. PMID: 38066116 -
Mol Cancer Ther
Mosperafenib, a novel paradox breaker BRAF inhibitor with potent preclinical activity in BRAF mutated colorectal cancer. [Abstract]2025 Dec 4. PMID: 41340484 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Appl Microbiol Biotechnol
Role of folic acid in regulating gut microbiota and short-chain fatty acids based on an in vitro fermentation model. [Abstract]2024 Dec;108(1):1-15. PMID: 38175236 -
Mol Oncol
Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]2026 Jun 5. PMID: 42246237 -
Mol Oncol
Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. [Abstract]2020 Nov;14(11):2894-2919. PMID: 33021054
Folinic acid purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2020 Nov;14(11):2894-2919. [Abstract]
FOLFOX was administered as 6 mg/kg Oxaliplatin two hours before administration of 90 mg/kg Leucovorin and 50 mg/kg 5-Fluorouracil at day 1 and a repeat of 5‐Fluorouracil dosing on day 2. Weight loss of ODC-, CTRL-, and FOLFOX-treated mice over time of mice with DLD1 tumors.
Folinic acid purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2020 Nov;14(11):2894-2919. [Abstract]
The corresponding panels show the activity of ODC, the corresponding monotherapy, and FOLFOX (0.5 µM Leucovorin, 5-Fluorouracil, Oxaliplatin), measured by comparing ATP levels in CRC cells (colored bars) and healthy CCD841 colonic epithelial cells (black bars) with CTRL (<0.15% DMSO), thus obtaining the treatment window (TW).
-
Int J Immunopathol Pharmacol
Chemotherapy elevates cell surface PD-L1 and MHC-I expression in apoptotic gastric cancer cells. [Abstract]2025 Jan-Dec:39:3946320251338662. PMID: 40380807
Folinic acid purchased from MedChemExpress. Usage Cited in: Int J Immunopathol Pharmacol. 2025 Jan-Dec:39:3946320251338662. [Abstract]
Effects of FOLFOX on surface PD-L1 expression on AGS cells. Cells were treated with FOLFOX (Leucovorin: 14 μM; 5-Fu: 200 μM; Oxaliplatin: 6 μM) for 48 h. Then, cells were co-stained with annexin V and PD-L1 antibody. Representative histogram showing surface PD-L1 expression. Red histogram: total cells. Purple histogram: annexin V-positive cells.
Folinic acid purchased from MedChemExpress. Usage Cited in: Int J Immunopathol Pharmacol. 2025 Jan-Dec:39:3946320251338662. [Abstract]
Effects of FOLFOX on surface MHC-I expression on AGS cells. Cells were treated with FOLFOX (Leucovorin: 14 μM; 5-Fu: 200 μM; Oxaliplatin: 6 μM) for 48 h. Then, cells were co-stained with annexin V and MHC-I antibody. Representative dot plots showing the expression of annexin V and surface MHC-I on AGS cells.
-
Virology
Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. [Abstract]2023 Aug:585:205-214. PMID: 37384967
Folinic acid purchased from MedChemExpress. Usage Cited in: Virology. 2023 Aug:585:205-214. [Abstract]
Leucovorin (10 μM; 48 h). VP1 protein levels were detected using Western blot.
-
Oncol Lett
Leucovorin enhances curcumin-induced inhibition of cell viability and ferroptosis in colorectal cancer cells. [Abstract]2026 Mar 4;31(5):155. PMID: 41852897 -
-
-
Solvant et solubilité
DMSO : 175 mg/mL (369.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Keshava, C., et al., Inhibition of methotrexate-induced chromosomal damage by folinic acid in V79 cells. Mutat Res, 1998. 397(2): p. 221-8. [Content Brief]
[2]. Iqbal MP, et al. Effect of methotrexate and folinic acid on skeletal growth in mice. Acta Paediatr. 2003 Dec;92(12):1438-44. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1122 mL | 10.5610 mL | 21.1220 mL | 52.8050 mL |
| 5 mM | 0.4224 mL | 2.1122 mL | 4.2244 mL | 10.5610 mL | |
| 10 mM | 0.2112 mL | 1.0561 mL | 2.1122 mL | 5.2805 mL | |
| 15 mM | 0.1408 mL | 0.7041 mL | 1.4081 mL | 3.5203 mL | |
| 20 mM | 0.1056 mL | 0.5281 mL | 1.0561 mL | 2.6403 mL | |
| 25 mM | 0.0845 mL | 0.4224 mL | 0.8449 mL | 2.1122 mL | |
| 30 mM | 0.0704 mL | 0.3520 mL | 0.7041 mL | 1.7602 mL | |
| 40 mM | 0.0528 mL | 0.2640 mL | 0.5281 mL | 1.3201 mL | |
| 50 mM | 0.0422 mL | 0.2112 mL | 0.4224 mL | 1.0561 mL | |
| 60 mM | 0.0352 mL | 0.1760 mL | 0.3520 mL | 0.8801 mL | |
| 80 mM | 0.0264 mL | 0.1320 mL | 0.2640 mL | 0.6601 mL | |
| 100 mM | 0.0211 mL | 0.1056 mL | 0.2112 mL | 0.5281 mL |
Folinic acid Related Classifications
HY-17556 Related Classifications
Powered by Bioz